Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
This is an open label compassionate use trial of Ublituximab and TGR-1202 in combination or as single agents in patients currently receiving treatment on Ublituximab and/or TGR-1202 trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.
Chronic Lymphocytic Leukemia|Non Hodgkin Lymphoma
DRUG: TGR-1202|DRUG: TGR-1202 + Ublituximab
Adverse Events of TGR-1202 and/or TGR-1202 + ublituximab treatment, including delayed toxicities, Toxicity according to the investigator (Adverse events with NCI-CTC 4.0), Evaluated at each planned visit through study completion, an average of 2 years
Progression-free survival of TGR-1202 and/or TGR-1202 + ublituximab treatment, Date of progression reported for each patient, Evaluated at each planned visit through study completion, an average of 2 years
This is an open label compassionate use trial of Ublituximab and TGR-1202 in combination or as single agents in patients currently receiving treatment on Ublituximab and/or TGR-1202 trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.